Department of Oncology, University Hospital Zagreb, Kispaticeva 12, Zagreb, Croatia.
Med Oncol. 2011 Dec;28 Suppl 1:S121-8. doi: 10.1007/s12032-010-9738-2. Epub 2010 Nov 23.
Recent interest of many investigators is focused on epidermal growth factor receptor (EGFR) family, because of their potential role in the pathogenesis and progression of breast cancer. Paraffin tumor sections were collected retrospectively from 181 breast cancer patients diagnosed between 2002 and 2003. Immunohistochemical staining with ErbB-1, ErbB-2, ErbB-3, and ErbB-4 monoclonal antibodies was performed. The ErbB expression was correlated with the other clinicopathological variables. Overexpression of ErbB-1, ErbB-2, ErbB-3, and ErbB-4 was observed in 20.6, 18.2, 14.3, and 5.7% cases, respectively. Overexpression of ErbB-1 and ErbB-2 was associated with poor prognostic features and decreased 5-year disease-free survival. The patients with co-overexpression of ErbB-1 and ErbB-2 had a shorter DFS, although this difference was not statistically significant. ErbB-1 overexpression may indicate a subset of patients with a poor disease prognosis. Assays for ErbB-1 and ErbB-2 may be more useful than a single assay in predicting prognosis of a breast cancer patient.
最近，许多研究人员对表皮生长因子受体（EGFR）家族产生了浓厚的兴趣，因为它们在乳腺癌的发病机制和进展中具有潜在作用。本研究回顾性收集了 2002 年至 2003 年间诊断的 181 例乳腺癌患者的石蜡肿瘤切片。采用 ErbB-1、ErbB-2、ErbB-3 和 ErbB-4 单克隆抗体进行免疫组织化学染色。分析 ErbB 表达与其他临床病理变量的相关性。结果显示，ErbB-1、ErbB-2、ErbB-3 和 ErbB-4 的过表达率分别为 20.6%、18.2%、14.3%和 5.7%。ErbB-1 和 ErbB-2 的过表达与不良预后特征相关，5 年无病生存率降低。尽管 ErbB-1 和 ErbB-2 共过表达的患者无病生存率（DFS）较短，但差异无统计学意义。ErbB-1 过表达可能预示着患者预后不良。与单一检测相比，ErbB-1 和 ErbB-2 的检测可能更有助于预测乳腺癌患者的预后。
